Andarix Pharmaceuticals CEO to Chair Rare Disease Clinical Trials Conference
(YorkPedia Editorial):- Cambridge, Massachusetts Sep 17, 2023 (Issuewire.com) – Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for rare cancers announced today that its CEO, Chris Adams will Chair the two days conference on rare diseases. The conference will include attendees from industry experts to patient groups.
The Clinical Trials in Rare Diseases Conference. This event will explore the challenges in clinical trials for orphan drugs and rare diseases, bringing together clinical operations professionals from across multiple therapeutic areas to discuss common obstacles and solutions. Topics at the conference include: the benefits of early planning and engagement with regulatory authorities, the importance of working closely with patients and patient advocacy groups, recruiting and retaining patients for rare disease studies.
More on YorkPedia:
- Innovating for Growth: How Investment Promotion Agencies are Shaping the Future of Global Business
- Keep Your Content 100% Original with Small SEO Tools Plagiarism Checker
- McKenzie Frishkorn, Recognized by BestAgents.us as a 2023 Top Agent
- O’Neill Fernandes Extends His Musical Collection with 48th Album ‘Price Tag’
- Grab the Opportunity of SoundCloud Music Promotion with Music Promotion Club
(YorkPedia Editorial):- Cambridge, Massachusetts Sep 17, 2023 (Issuewire.com) – Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for rare cancers announced today that its CEO, Chris Adams will Chair the two days conference on rare diseases. The conference will include attendees from industry experts to patient groups.
The Clinical Trials in Rare Diseases Conference. This event will explore the challenges in clinical trials for orphan drugs and rare diseases, bringing together clinical operations professionals from across multiple therapeutic areas to discuss common obstacles and solutions. Topics at the conference include: the benefits of early planning and engagement with regulatory authorities, the importance of working closely with patients and patient advocacy groups, recruiting and retaining patients for rare disease studies.
This article was originally published by IssueWire. Read the original article here.